PTR1 (Leishmania major, Q01782) - curation notes
Note: Automated deep research (Falcon/OpenAI) was unavailable in this environment.
These notes are a manual literature review based on the UniProt record, the cached
publications, and targeted PubMed/web searches. All PMIDs below were verified against
PubMed (esummary titles) before caching.
Identity
- Pteridine reductase 1, EC 1.5.1.33; synonyms HMTXR (H-region methotrexate resistance
protein), LmjF.23.0270. 288 aa, short-chain dehydrogenase/reductase (SDR) family,
homotetramer (UniProt).
- Originally identified as the amplified H-region gene conferring methotrexate (MTX)
resistance PMID:1339441.
That paper placed it in the aldo-keto reductase grouping; later kinetic/stereochemical
work placed it firmly in the SDR family PMID:9521731.
Molecular function
- NADPH-dependent reduction of unconjugated pterins (biopterin -> H2B -> H4B) and folates:
PMID:7972081
PMID:7972081
- Two-step reduction mechanism, structurally resolved:
PMID:11373620
PMID:11373620
- Folate -> DHF -> THF (DHFR-like reaction, same stereochemistry):
PMID:9521731
PMID:9521731
-> supports NEW GO:0004146 dihydrofolate reductase activity (GO definition: THF + NADP+ = DHF + NADPH).
This is not in GOA for Q01782. PTR1 is the catalyst, so no participation concern.
- Tetramer: PMID:9153248.
- MTX insensitivity relative to DHFR-TS: PMID:9153248.
Quinonoid dihydropteridine reductase (QDPR) activity - conflicting evidence
- Bello 1994 reported no activity with qH2B (quote above, PMID:7972081; abstract only).
- Ong 2011 (full text) used an HPLC/spectrophotometric assay and found NADPH-dependent
QDPR activity in both TbPTR1 and LmPTR1:
PMID:21239486
PMID:21239486
- So GO:0004155 6,7-dihydropteridine reductase activity (IDA, PMID:21239486) is supported, but in
L. major the dedicated LmQDPR is ~20-fold more efficient, so this is a secondary activity
for LmPTR1 (the dual role is more important in T. brucei, which lacks QDPR). Keep as non-core.
- The UniProt FUNCTION comment still carries the 1994 negative statement; newer data supersede it.
Biological process
- Pterin salvage: Leishmania are pterin auxotrophs; PTR1 is the primary salvage enzyme:
PMID:7972081
PMID:9153248
-> GO:0006729 tetrahydrobiopterin biosynthetic process (IEA, UniPathway) is appropriate: the
enzyme catalyses the formation of H4B from biopterin (salvage rather than de novo GTP route,
which kinetoplastids lack PMID:21239486).
- Antifolate resistance: PTR1 amplification confers MTX resistance (bypass of DHFR-TS and/or drug
sequestration). This is a pharmacological phenotype, not a normal biological process; I did not
propose "response to methotrexate".
- Downstream phenotypes (metacyclogenesis, oxidative stress sensitivity of ptr1- mutants; glycosome
and cytokinesis defects in T. brucei RNAi) are consequences of H4B depletion, not processes PTR1
executes; no process terms proposed for these.
PMID:20545846
Localization
- T. brucei PTR1 (ortholog, ISO donor Tb927.8.2210) fractionates with cytosol:
PMID:20545846
- L. donovani PTR1-GFP is cytoplasmic:
PMID:17275814
- No evidence for glycosomal localization (no PTS1; despite a database-level glycosome mention in
LeishmaniaDB, which lacked protein-level evidence). Cytosol ISO accepted.
- L. donovani PTR1 is degraded in stationary phase, proposed proteasome-mediated (PMID:17275814),
linking lower H4B with metacyclogenesis.
Annotation decisions summary
| term |
evidence |
action |
| GO:0047040 pteridine reductase activity |
IDA, IEA, ISO |
ACCEPT (core) |
| GO:0004155 6,7-dihydropteridine reductase activity |
IDA |
KEEP_AS_NON_CORE |
| GO:0006729 tetrahydrobiopterin biosynthetic process |
IEA |
ACCEPT |
| GO:0005829 cytosol |
ISO |
ACCEPT |
| GO:0016491 oxidoreductase activity |
IBA, ISM |
MODIFY -> GO:0047040, GO:0004146 |
| GO:0004146 dihydrofolate reductase activity |
- |
NEW |
Protist-specific checks
- No animal/plant-only terms transferred. No organelle mismatches (cytosol is consistent with
data). Not part of trypanothione or RNA editing pathways. No host-process terms. SDR family
is huge; IBA/ISM rows only assert generic oxidoreductase, so no paralog over-annotation, just
under-specificity.